Read
- Egypt on the edge after Mursi rebuffs army ultimatum
|
- Snowden threatens new U.S. leaks, asks numerous countries for asylum
- Diverging growth outlook drives shares, dollar firm
- Snowden in transit area, drops Russia asylum request - Kremlin
- Exclusive: Greece has three days to deliver or face consequences - EU officials
Sponsored Links
FDA rejects Merck's insomnia drug
July 1 |
July 1 (Reuters) - Merck & Co Inc said the U.S. Food and Drug Administration rejected the company's experimental insomnia drug, citing safety issues.
In a complete response letter to the company, the FDA said the safety data of the drug do not support approval, and advised that lower doses of the medicine should be made available before an approval.
The efficacy of the drug, suvorexant, was established at doses of 10 mg to 40 mg in adults, the FDA said, adding that 10 mg should be the starting dose for most patients.
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (0)
Be the first to comment on reuters.com.
Add yours using the box above.
Follow Reuters